Monday, November 10, 2025

In Detail Full day, Monday, November 10, 2025, Timezone: America/Chicago

Canada loses measles elimination status after ongoing outbreaks

go - International health experts say Canada is no longer measles-free because of ongoing outbreaks, as childhood vaccination rates fall and the highly contagious virus spreads across North and South America

AI Summary: Health experts report that Canada has lost its measles elimination status amid large-scale outbreaks and falling vaccination rates. The loss, confirmed by multiple sources, has raised public health alarms and may affect regional disease control efforts.

FDA rolls back warning labels on HRT products for menopause, citing misinformation

fiercehealthcare - The action, announced Monday, follows a comprehensive review of scientific literature by an expert panel at the agency in July, as well as a public comment period, officials said. Pharmas are expected to update and reprint their product labeling to remove…

AI Summary: Following a rigorous review of the scientific evidence, federal regulators are scrapping boxed warnings on hormone replacement products used for menopausal symptom relief. The move—aimed at increasing treatment access—casts a skeptical eye on long-held safety fears, inviting both applause and a few sarcastic raised eyebrows in the industry.

Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera

Frank Vinluan / medcitynews - Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favo…

AI Summary: In a dramatic showdown over obesity biotech firm Metsera, Pfizer’s up-to-$10B cash offer edged out Novo Nordisk’s bid. The fiercely competitive deal highlights the high stakes and intense market focus on innovative therapeutics in obesity management.